A Double-Blind, Randomized, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2019
At a glance
- Drugs AB-680 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arcus Biosciences
- 21 Dec 2018 Planned number of patients changed from 16 to 32.
- 21 Dec 2018 Planned End Date changed from 18 Mar 2019 to 28 May 2019.
- 21 Dec 2018 Planned primary completion date changed from 18 Mar 2019 to 28 May 2019.